{"DataElement":{"publicId":"6942264","version":"1","preferredName":"Autoimmune Disease Type","preferredDefinition":"The type of disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.","longName":"2677305v1.0:6942263v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"2677305","version":"1","preferredName":"Autoimmune Disease Type","preferredDefinition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.  It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis). -- 2003_Something distinguishable as an identifiable class based on common qualities.","longName":"AIMN_DIS_TYPE","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2677302","version":"1","preferredName":"Autoimmune Disease","preferredDefinition":"A condition in which the body recognizes its own tissues as foreign and directs an immune response against them.","longName":"C2889","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Disease","conceptCode":"C2889","definition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39666774-DD1C-1E12-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-05","modifiedBy":"ONEDATA","dateModified":"2007-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223243","version":"1","preferredName":"Type","preferredDefinition":"A subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629F5E5-DE63-1DFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39666774-DD3E-1E12-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"3/24/2010-Added CSI for F2000 per F2000 modifications-CJL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6942263","version":"1","preferredName":"Autoimmune Disease Type","preferredDefinition":"The type of disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.","longName":"6942263v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"250","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-7521-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Vitiligo","valueDescription":"Vitiligo","ValueMeaning":{"publicId":"3252121","version":"1","preferredName":"Vitiligo","longName":"3252121","preferredDefinition":"A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitiligo","conceptCode":"C26915","definition":"Generalized well circumscribed patches of leukoderma that are generally distributed over symmetric body locations and is due to autoimmune destruction of melanocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A781D14A-E71E-8A44-E040-BB89AD4310FD","latestVersionIndicator":"Yes","beginDate":"2011-07-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-752B-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Vasculitis","valueDescription":"Vasculitis","ValueMeaning":{"publicId":"2943908","version":"1","preferredName":"Vasculitis","longName":"2943908","preferredDefinition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener's granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasculitis","conceptCode":"C26912","definition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742B257F-AAE1-95B9-E040-BB89AD4354AE","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-7535-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Thyroiditis","valueDescription":"Thyroiditis","ValueMeaning":{"publicId":"3249063","version":"1","preferredName":"Thyroiditis","longName":"3249063","preferredDefinition":"Inflammation of the thyroid gland. Thyroiditis may be an autoimmune disease that affects the thyroid gland over time, causing hypothyroidism (too little thyroid hormone). A temporary form of thyroiditis may also occur after the birth of a baby, or when viral or bacterial infections spread to the thyroid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroiditis","conceptCode":"C26894","definition":"Inflammation of the thyroid gland. This category includes Hashimoto thyroiditis, Riedel thyroiditis, acute thyroiditis, subacute thyroiditis, and radiation-induced thyroiditis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-1938-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-7549-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Polymyalgia rheumatica","valueDescription":"Polymyalgia Rheumatica","ValueMeaning":{"publicId":"3211374","version":"1","preferredName":"Polymyalgia Rheumatica","longName":"3211374","preferredDefinition":"A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymyalgia Rheumatica","conceptCode":"C85018","definition":"A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F4DB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-755D-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Pernicious anemia","valueDescription":"Pernicious Anemia","ValueMeaning":{"publicId":"3210758","version":"1","preferredName":"Pernicious Anemia","longName":"3210758","preferredDefinition":"Megaloblastic anemia caused by vitamin B-12 deficiency due to impaired absorption. The impaired absorption of vitamin B-12 is secondary to atrophic gastritis and loss of gastric parietal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pernicious Anemia","conceptCode":"C2871","definition":"Megaloblastic anemia caused by vitamin B-12 deficiency due to impaired absorption. The impaired absorption of vitamin B-12 is secondary to atrophic gastritis and loss of gastric parietal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9ADA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-7572-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Hashimoto's thyroiditis","valueDescription":"Hashimoto Thyroiditis","ValueMeaning":{"publicId":"3211123","version":"1","preferredName":"Hashimoto Thyroiditis","longName":"3211123","preferredDefinition":"An autoimmune disorder caused by the production of autoantibodies against thyroid tissue. There is progressive destruction of the thyroid follicles leading to hypothyroidism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hashimoto Thyroiditis","conceptCode":"C27191","definition":"An autoimmune disorder caused by the production of autoantibodies against thyroid tissue. There is progressive destruction of the thyroid follicles leading to hypothyroidism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D10E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-7587-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ZHWENDY","dateModified":"2022-07-18","deletedIndicator":"No"},{"value":"Graves' disease","valueDescription":"Graves disease","ValueMeaning":{"publicId":"5417297","version":"1","preferredName":"Graves disease","longName":"5417297","preferredDefinition":"Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secrets increased amounts of thyroid hormones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graves Disease","conceptCode":"C3071","definition":"Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A49A30E-42D1-4645-E050-BB89AD432879","latestVersionIndicator":"Yes","beginDate":"2016-08-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-759B-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ZHWENDY","dateModified":"2022-07-18","deletedIndicator":"No"},{"value":"Celiac disease","valueDescription":"Celiac Disease","ValueMeaning":{"publicId":"3249580","version":"1","preferredName":"Celiac Disease","longName":"3249580","preferredDefinition":"A digestive disease that is caused by an immune response to a protein called gluten, which is found in wheat, rye, barley, and oats. Celiac disease damages the lining of the small intestine and interferes with the absorption of nutrients from food. A person with celiac disease may become malnourished no matter how much food is consumed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Celiac Disease","conceptCode":"C26714","definition":"An autoimmune genetic disorder with an unknown pattern of inheritance that primarily affects the digestive tract. It is caused by intolerance to dietary gluten. Consumption of gluten protein triggers an immune response which damages small intestinal villi and prevents adequate absorption of nutrients. Clinical signs include abdominal cramping, diarrhea or constipation and weight loss. If untreated, the clinical course may progress to malnutrition, anemia, osteoporosis and an increased risk of intestinal malignancies. However, the prognosis is favorable with successful avoidance of gluten in the diet.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D99025-BE2B-DBB4-E040-BB89AD434418","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-75A5-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Alopecia areata","valueDescription":"Alopecia","ValueMeaning":{"publicId":"2946575","version":"1","preferredName":"Alopecia","longName":"2946575","preferredDefinition":"Hair loss usually from the scalp. It may result in bald spots or spread to the entire scalp or the entire epidermis. It may be androgenetic or caused by chemotherapeutic agents, compulsive hair pulling, autoimmune disorders or congenital conditions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alopecia","conceptCode":"C50575","definition":"Hair loss usually from the scalp. It may result in bald spots or spread to the entire scalp or the entire epidermis. It may be androgenetic or caused by chemotherapeutic agents, compulsive hair pulling, autoimmune disorders or congenital conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74A54D4F-9F68-0EDF-E040-BB89AD430BAB","latestVersionIndicator":"Yes","beginDate":"2009-09-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-09-28","modifiedBy":"COOPERM","dateModified":"2020-04-16","changeDescription":"Updated definition to current NCIt. mc 4/16/20","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-75B9-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Addison's disease","valueDescription":"Addison's Disease","ValueMeaning":{"publicId":"3210845","version":"1","preferredName":"Addison's Disease","longName":"3210845","preferredDefinition":"A hormonal disorder that occurs when the adrenal glands fail to release adequate amounts of glucocorticoids (cortisol), mineralocorticoids (aldosterone, 11-deoxycorticosterone), and androgens (dehydroepiandrosterone) to meet physiologic needs, despite release of ACTH from the pituitary.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Addison's Disease","conceptCode":"C26689","definition":"A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A994-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-75CE-6C01-E053-F662850A21E9","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ZHWENDY","dateModified":"2022-07-18","deletedIndicator":"No"},{"value":"Crohn's disease","valueDescription":"Crohn Disease","ValueMeaning":{"publicId":"2577525","version":"1","preferredName":"Crohn Disease","longName":"2577525","preferredDefinition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn's disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crohn Disease","conceptCode":"C2965","definition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-75D8-6C01-E053-F662850A21E9","beginDate":"2007-09-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Diabetes mellitus type I","valueDescription":"Type 1 Diabetes Mellitus","ValueMeaning":{"publicId":"5054471","version":"1","preferredName":"Type 1 Diabetes Mellitus","longName":"5054471","preferredDefinition":"A chronic condition characterized by minimal or absent production of insulin by the pancreas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type 1 Diabetes Mellitus","conceptCode":"C2986","definition":"A chronic condition characterized by minimal or absent production of insulin by the pancreas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"25628B4B-6B65-594C-E050-BB89AD430F0C","latestVersionIndicator":"Yes","beginDate":"2015-11-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-75E2-6C01-E053-F662850A21E9","beginDate":"2015-11-25","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Multiple sclerosis","valueDescription":"multiple sclerosis","ValueMeaning":{"publicId":"2579888","version":"1","preferredName":"multiple sclerosis","longName":"2579888","preferredDefinition":"A disorder of the central nervous system marked by weakness, numbness, a loss of muscle coordination, and problems with vision, speech, and bladder control. Multiple sclerosis is thought to be an autoimmune disease in which the body's immune system destroys myelin. Myelin is a substance that contains both protein and fat (lipid), serving as a nerve insulator and helping in the transmission of nerve signals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Sclerosis","conceptCode":"C3243","definition":"A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-051D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-75EC-6C01-E053-F662850A21E9","beginDate":"2007-09-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Myasthenia gravis","valueDescription":"Myasthenia Gravis","ValueMeaning":{"publicId":"3143924","version":"1","preferredName":"Myasthenia Gravis","longName":"3143924","preferredDefinition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness.  It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myasthenia Gravis","conceptCode":"C60989","definition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9167B9F7-3DD6-C748-E040-BB89AD432898","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-29","modifiedBy":"KUMMEROA","dateModified":"2022-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-75F6-6C01-E053-F662850A21E9","beginDate":"2007-09-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Psoriasis","valueDescription":"Psoriasis","ValueMeaning":{"publicId":"2567418","version":"1","preferredName":"Psoriasis","longName":"2567418","preferredDefinition":"A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psoriasis","conceptCode":"C3346","definition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D467-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-7600-6C01-E053-F662850A21E9","beginDate":"2010-06-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Rheumatoid arthritis","valueDescription":"Rheumatoid Arthritis","ValueMeaning":{"publicId":"2570667","version":"1","preferredName":"Rheumatoid Arthritis","longName":"2570667","preferredDefinition":"A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rheumatoid Arthritis","conceptCode":"C2884","definition":"A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E118-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CZECHS","dateModified":"2008-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-760A-6C01-E053-F662850A21E9","beginDate":"2007-09-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Sjogren's syndrome","valueDescription":"Sjogren's Syndrome","ValueMeaning":{"publicId":"2593564","version":"1","preferredName":"Sjogren's Syndrome","longName":"2593564","preferredDefinition":"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sjogren Syndrome","conceptCode":"C26883","definition":"An autoimmune disorder affecting the salivary and lacrimal glands. Morphologically, it is characterized by the presence of lymphocytic and plasmacytic infiltrates which cause destruction of these glands. It results in dry mouth and dry eyes. It may be associated with the presence of other autoimmune disorders, including rheumatoid arthritis and lupus erythematosus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BED297-469F-6CF9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-761E-6C01-E053-F662850A21E9","beginDate":"2007-09-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Ulcerative colitis","valueDescription":"Ulcerative Colitis","ValueMeaning":{"publicId":"2577524","version":"1","preferredName":"Ulcerative Colitis","longName":"2577524","preferredDefinition":"Inflammatory disease of unknown cause which involves the mucosa of the colon. Onset may be acute and fulminant, and its course often continues chronically in an intermittent or continuous form. Diarrhea is a common symptom and bleeding an almost constant concomitant symptom.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ulcerative Colitis","conceptCode":"C2952","definition":"An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"CZECHS","dateModified":"2008-06-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DF27B2-763C-6C01-E053-F662850A21E9","beginDate":"2007-09-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Systemic lupus erythematosus","valueDescription":"Systemic Lupus Erythematosus","ValueMeaning":{"publicId":"2593562","version":"1","preferredName":"Systemic Lupus Erythematosus","longName":"2593562","preferredDefinition":"A chronic inflammatory connective tissue disease marked by skin rashes, joint pain and swelling, inflammation of the kidneys, inflammation of the fibrous tissue surrounding the heart (i.e., the pericardium), as well as other problems.  Not all affected individuals display all of these problems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Lupus Erythematosus","conceptCode":"C3201","definition":"An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BED21B-19CD-6CE2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92E9D5CB-A51B-7901-E053-F662850A1CA9","beginDate":"2007-09-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2486855","version":"1","preferredName":"Autoimmune Disease Type","preferredDefinition":"A condition in which the body recognizes its own tissues as foreign and directs an immune response against them.:Type; a subdivision of a particular kind of thing.","longName":"C2889:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Disease","conceptCode":"C2889","definition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16485CD4-9201-236E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-15","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-15","modifiedBy":"ONEDATA","dateModified":"2006-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"92DF27B2-750A-6C01-E053-F662850A21E9","latestVersionIndicator":"Yes","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"ZHWENDY","dateModified":"2022-07-18","changeDescription":"3/4/2020: CM Released as part of draft content review","administrativeNotes":"7/18/2022: fixed the box symbol in PVs.wz","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Autoimmune Disease","type":"Preferred Question Text","description":"Autoimmune Disease","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"92E81765-0351-6B7A-E053-F662850A7A5E","latestVersionIndicator":"Yes","beginDate":"2019-09-19","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-19","modifiedBy":"MORENOC","dateModified":"2020-03-04","changeDescription":"3/4/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}